open access

Vol 84, No 11 (2013)
ARTICLES
Get Citation

Expression of E-cadherin and β1-integrin mRNA in endometrial cancer

Katarzyna Wójcik-Krowiranda, Ewa Forma, Agnieszka Zaczek, Magdalena Bryś, Magdalena Krześlak, Andrzej Bieńkiewicz
DOI: 10.17772/gp/1659
·
Ginekol Pol 2013;84(11).

open access

Vol 84, No 11 (2013)
ARTICLES

Abstract

Objectives: The metastatic ability of tumors is characteristic for malignant neoplasms and constitutes the main cause of therapeutics failures. Metastasis formation involves the sequence of processes such as proteolytic degradation of the basement membrane, migration, intravasation, extravasation, proliferation and angiogenesis. Cadherins and integrins are groups of proteins directly involved in these processes. In the present study we analyzed the mRNA expression of CDH1 and ITGB1 genes by real-time polymerase chain reaction (RT-PCR). The study included 106 endometrial carcinomas. CDH1 and ITGB1 mRNA expression was found in all of the studied samples. Generally, the CDH1 and ITGB1 mRNA expression was significantly higher in well-differentiated rather than poorly differentiated tumors. Materials and methods: The mRNA expression levels of CDH1 and ITGB1 in series of 83 samples of endometrial carcinoma were studied by real time RT-PCR method. Statistical analysis of the obtained results was performed. Results: CDH1 and ITGB1 gene expression was observed in all examined tissues and was correlated with cancer malignancy (G). In high grade malignant tumors (G1), CDH1 and ITGB1 gene expression was the highest, in G2 and G3 tumors the expression of both genes was gradually lowering. Moreover, the statistically significant correlation between CDH1 and ITGB1 gene expression was observed. (Spearman test, r=0.29, p<0.01). Conclusion: CDH1 and ITGB1 mRNA expression seems to be an important marker of cancer progression and metastases in endometrial malignant tumors.

Abstract

Objectives: The metastatic ability of tumors is characteristic for malignant neoplasms and constitutes the main cause of therapeutics failures. Metastasis formation involves the sequence of processes such as proteolytic degradation of the basement membrane, migration, intravasation, extravasation, proliferation and angiogenesis. Cadherins and integrins are groups of proteins directly involved in these processes. In the present study we analyzed the mRNA expression of CDH1 and ITGB1 genes by real-time polymerase chain reaction (RT-PCR). The study included 106 endometrial carcinomas. CDH1 and ITGB1 mRNA expression was found in all of the studied samples. Generally, the CDH1 and ITGB1 mRNA expression was significantly higher in well-differentiated rather than poorly differentiated tumors. Materials and methods: The mRNA expression levels of CDH1 and ITGB1 in series of 83 samples of endometrial carcinoma were studied by real time RT-PCR method. Statistical analysis of the obtained results was performed. Results: CDH1 and ITGB1 gene expression was observed in all examined tissues and was correlated with cancer malignancy (G). In high grade malignant tumors (G1), CDH1 and ITGB1 gene expression was the highest, in G2 and G3 tumors the expression of both genes was gradually lowering. Moreover, the statistically significant correlation between CDH1 and ITGB1 gene expression was observed. (Spearman test, r=0.29, p<0.01). Conclusion: CDH1 and ITGB1 mRNA expression seems to be an important marker of cancer progression and metastases in endometrial malignant tumors.
Get Citation

Keywords

Molecular marker, E-catherin

About this article
Title

Expression of E-cadherin and β1-integrin mRNA in endometrial cancer

Journal

Ginekologia Polska

Issue

Vol 84, No 11 (2013)

DOI

10.17772/gp/1659

Bibliographic record

Ginekol Pol 2013;84(11).

Keywords

Molecular marker
E-catherin

Authors

Katarzyna Wójcik-Krowiranda
Ewa Forma
Agnieszka Zaczek
Magdalena Bryś
Magdalena Krześlak
Andrzej Bieńkiewicz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl